Cargando…

Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis

BACKGROUND: Prognostic significance of the programmed death-ligand-1 status in non-small cell lung carcinoma remains controversial AIMS: To show the programmed death-ligand-1 expression status in patients with non-small cell lung carcinoma and its effect on the prognosis and the relationship with cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Şahin, Songül, Batur, Şebnem, Aydın, Övgü, Öztürk, Tülin, Turna, Akif, Öz, Büge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528525/ https://www.ncbi.nlm.nih.gov/pubmed/30592196 http://dx.doi.org/10.4274/balkanmedj.galenos.2018.2018.0392

Ejemplares similares

Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis
por: Batur, Sebnem, et al.
Publicado: (2020)

An intrapericardial thymoma resected by uniportal video-assisted thoracoscopic surgery
por: Kara, Hasan Volkan, et al.
Publicado: (2022)

A rare pediatric tumor: thymic carcinoma mimicking acute rheumatoid fever
por: Erguven, Muferet, et al.
Publicado: (2014)

Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma
por: Yülek, Özden, et al.
Publicado: (2022)

Adenocarcinoma in a Tailgut Cyst: A Rare Case Report
por: Şahin, Songül, et al.
Publicado: (2020)

Two smoking-related lesions in the same pulmonary lobe of squamous cell carcinoma and pulmonary Langerhans cell histiocytosis: A case report
por: Gencer, Aysegul, et al.
Publicado: (2022)

Comparison of Different ROS1 Immunohistochemistry Clones and Consistency with Fluorescence In Situ Hybridization Results in Non-Small Cell Lung Carcinoma
por: Dülger, Onur, et al.
Publicado: (2023)

The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis
por: Kaya Terzi, Neslihan, et al.
Publicado: (2019)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

The role of galectin-3 and its genetic variants in tumor risk and survival of patients with surgically resected early-stage non-small cell lung cancer
por: Terzioğlu-Uşak, Şule, et al.
Publicado: (2021)

Concordance of PD-L1 expression and CD8(+) TIL intensity between NSCLC and synchronous brain metastases
por: Batur, Sebnem, et al.
Publicado: (2020)

The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures
por: Shi, Tao, et al.
Publicado: (2021)

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
por: Acheampong, Emmanuel, et al.
Publicado: (2019)

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)

Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon
por: Fakhri, Ghina, et al.
Publicado: (2021)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Is it possible to predict atherosclerosis in the ascending aorta by the patient’s lipid panel?
por: Haberal, İsmail, et al.
Publicado: (2020)

Pleomorphic Carcinoma of the Lung with High Serum Beta-human Chorionic Gonadotropin Level and Gynecomastia
por: Okutur, Kerem, et al.
Publicado: (2010)

Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
por: Cheng, Ying, et al.
Publicado: (2021)

Olfactory Neuroblastomas: An Experience of 24 Years
por: Tural, Deniz, et al.
Publicado: (2011)

Effect of trail C1595T variant and gene expression on the pathogenesis of non-small cell lung cancer
por: Koç Erbaşoğlu, Öncü, et al.
Publicado: (2018)

Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer
por: Cui, Shaohua, et al.
Publicado: (2017)

Programmed death ligand‐1 expression and occult lymph node metastasis in non‐small cell lung cancer
por: Mitsui, Suguru, et al.
Publicado: (2023)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
por: Lee, Yong Jun, et al.
Publicado: (2021)

A rare tumor of the gallbladder: Small cell neuroendocrine carcinoma
por: Kepil, Nuray, et al.
Publicado: (2019)

Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer
por: Sun, Hui, et al.
Publicado: (2021)

Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment
por: Li, Aixin, et al.
Publicado: (2022)

Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples
por: Soo, Ross A., et al.
Publicado: (2018)

Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
por: Vecchiarelli, Silvia, et al.
Publicado: (2018)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment
por: Li, Feng, et al.
Publicado: (2022)

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody
por: Murakami, Shuji, et al.
Publicado: (2020)

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy
por: Jin, Jianjun, et al.
Publicado: (2018)

The Effects of Modified Atmosphere Packaging on the Quality Properties of Water Buffalo Milk’s Concentrated Cream
por: Koyuncu, Mubin, et al.
Publicado: (2023)

Can postoperative complications be reduced by the application of ERAS protocols in operated non-small cell lung cancer patients?
por: Turna, Akif, et al.
Publicado: (2023)

Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis
por: Zhou, Tingting, et al.
Publicado: (2018)

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
por: de Castro, Gilberto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6fh5b2oi7oai4m1uvgnd01jp0h